Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Receives $34.33 Consensus Target Price from Analysts

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have received a consensus recommendation of “Hold” from the nine research firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $34.3333.

Several research firms have weighed in on LKFT. Zacks Research raised shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research note on Monday, June 8th. Morgan Stanley assumed coverage on Lakefront Biotherapeutics American Depositary Shares in a report on Friday, July 10th. They issued an “equal weight” rating and a $30.00 price objective on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Tuesday, May 26th. Finally, Wall Street Zen cut Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th.

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Shares of LKFT opened at $30.01 on Friday. The firm has a market cap of $1.98 billion, a price-to-earnings ratio of -21.28 and a beta of 0.25. Lakefront Biotherapeutics American Depositary Shares has a fifty-two week low of $26.42 and a fifty-two week high of $37.78. The firm has a 50 day moving average price of $28.64 and a 200-day moving average price of $30.74.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $0.25 EPS for the quarter, beating the consensus estimate of ($1.27) by $1.52. The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $11.26 million. As a group, equities research analysts predict that Lakefront Biotherapeutics American Depositary Shares will post -10.83 earnings per share for the current year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Several hedge funds and other institutional investors have recently bought and sold shares of LKFT. ABC Arbitrage SA purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the first quarter valued at approximately $382,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the first quarter worth $248,000. QRG Capital Management Inc. increased its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 21.9% in the first quarter. QRG Capital Management Inc. now owns 19,705 shares of the biotechnology company’s stock worth $591,000 after buying an additional 3,535 shares during the period. XTX Topco Ltd raised its holdings in Lakefront Biotherapeutics American Depositary Shares by 92.6% during the 4th quarter. XTX Topco Ltd now owns 23,219 shares of the biotechnology company’s stock valued at $759,000 after buying an additional 11,162 shares during the last quarter. Finally, Millennium Management LLC raised its holdings in Lakefront Biotherapeutics American Depositary Shares by 121.9% during the 4th quarter. Millennium Management LLC now owns 339,354 shares of the biotechnology company’s stock valued at $11,097,000 after buying an additional 186,452 shares during the last quarter. Institutional investors own 32.46% of the company’s stock.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.